Fenofibrate, a PPARα agonist, has renoprotective effects in mice by enhancing renal lipolysis

Kidney International

Volumn 79, Issue 8, 2011, Pages 871-882

  Tanaka, Yuki ^a   Kume, Shinji ^a   Araki, Shin Ichi ^a   Isshiki, Keiji ^a   Chin Kanasaki, Masami ^a   Sakaguchi, Masayoshi ^a   Sugimoto, Toshiro ^a   Koya, Daisuke ^b   Haneda, Masakazu ^c   Kashiwagi, Atsunori ^a   Maegawa, Hiroshi ^a   Uzu, Takashi ^a  

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^b KANAZAWA MEDICAL UNIVERSITY   (Japan)

^c ASAHIKAWA MEDICAL COLLEGE   (Japan)

Author keywords

chronic kidney disease; lipolytic enzymes; pathophysiology; renal lipotoxicity

Indexed keywords

ACETYL COENZYME A CARBOXYLASE; ACYL COENZYME A OXIDASE; ALBUMIN; CARNITINE PALMITOYLTRANSFERASE I; CATALASE; CHOLESTEROL; COPPER ZINC SUPEROXIDE DISMUTASE; FATTY ACID; FENOFIBRATE; FIBRONECTIN; GLUCOSE; HEMOGLOBIN A1C; INSULIN; LIPID; MANGANESE SUPEROXIDE DISMUTASE; MEDIUM CHAIN ACYL COENZYME A DEHYDROGENASE; MONOCYTE CHEMOTACTIC PROTEIN 1; PALMITIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PLASMINOGEN ACTIVATOR INHIBITOR 1; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; TRIACYLGLYCEROL;

ALBUMINURIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; CELL CULTURE; CELL INFILTRATION; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; GLOMERULUS; INHIBITION KINETICS; KIDNEY FIBROSIS; KIDNEY INTERSTITIUM; KIDNEY PROXIMAL TUBULE; KIDNEY TUBULE DAMAGE; LIPID DIET; LIPID STORAGE; LIPOLYSIS; MACROPHAGE; MALE; MESANGIUM CELL; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENAL PROTECTION;

EID: 79953240855     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2010.530     Document Type: Article

References (35)

1. Go AS, Chertow GM, Fan D et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-1305.
2. Abrass CK. Cellular lipid metabolism and the role of lipids in progressive renal disease. Am J Nephrol 2004; 24: 46-53. (Pubitemid 38258276)
3. Bagby SP. Obesity-initiated metabolic syndrome and the kidney: a recipe for chronic kidney disease? J Am Soc Nephrol 2004; 15: 2775-2791. (Pubitemid 41103387)
4. Schaffer JE. Lipotoxicity: when tissues overeat. Curr Opin Lipidol 2003; 14: 281-287. (Pubitemid 36688207)
5. Unger RH, Orci L. Diseases of liporegulation: new perspective on obesity and related disorders. FASEB J 2001; 15: 312-321. (Pubitemid 32141423)
6. Kume S, Uzu T, Araki S et al. Role of altered renal lipid metabolism in the development of renal injury induced by a high-fat diet. J Am Soc Nephrol 2007; 18: 2715-2723. (Pubitemid 47531198)
7. Wang Z, Jiang T, Li J et al. Regulation of renal lipid metabolism, lipid accumulation, and glomerulosclerosis in FVBdb/db mice with type 2 diabetes. Diabetes 2005; 54: 2328-2335. (Pubitemid 41134259)
8. Thomas ME, Schreiner GF. Contribution of proteinuria to progressive renal injury: consequences of tubular uptake of fatty acid bearing albumin. Am J Nephrol 1993; 13: 385-398. (Pubitemid 24014486)
9. Kamijo A, Kimura K, Sugaya T et al. Urinary free fatty acids bound to albumin aggravate tubulointerstitial damage. Kidney Int 2002; 62: 1628-1637. (Pubitemid 35286270)
10. Thomas ME, Harris KP, Walls J et al. Fatty acids exacerbate tubulointerstitial injury in protein-overload proteinuria. Am J Physiol Renal Physiol 2002; 283: F640-F647. (Pubitemid 35033950)
11. Risdon RA, Sloper JC, De Wardener HE. Relationship between renal function and histological changes found in renal-biopsy specimens from patients with persistent glomerular nephritis. Lancet 1968; 2: 363-366.
12. Dreyer C, Krey G, Keller H et al. Control of the peroxisomal beta-oxidation pathway by a novel family of nuclear hormone receptors. Cell 1992; 68: 879-887.
13. Schoonjans K, Staels B, Auwerx J. Role of the peroxisome proliferatoractivated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. J Lipid Res 1996; 37: 907-925. (Pubitemid 26182326)
14. Aoyama T, Peters JM, Iritani N et al. Altered constitutive expression of fatty acid-metabolizing enzymes in mice lacking the peroxisome proliferator-activated receptor alpha (PPARalpha). J Biol Chem 1998; 273: 5678-5684. (Pubitemid 28124039)
15. Braissant O, Foufelle F, Scotto C et al. Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology 1996; 137: 354-366. (Pubitemid 26005011)
16. Deji N, Kume S, Araki S et al. Structural and functional changes in the kidneys of high-fat diet-induced obese mice. Am J Physiol Renal Physiol 2009; 296: F118-F126.
17. Nagai Y, Nishio Y, Nakamura T et al. Amelioration of high fructoseinduced metabolic derangements by activation of PPARalpha. Am J Physiol Endocrinol Metab 2002; 282: E1180-E1190. (Pubitemid 34654734)
18. Koh E, Kim M, Park J et al. Peroxisome proliferator-activated receptor (PPAR)-alpha activation prevents diabetes in OLETF rats: comparison with PPAR-gamma activation. Diabetes 2003; 52: 2331-2337. (Pubitemid 37059504)
19. Shin S, Lim J, Chung S et al. Peroxisome proliferator-activated receptor-alpha activator fenofibrate prevents high-fat diet-induced renal lipotoxicity in spontaneously hypertensive rats. Hypertens Res 2009; 32: 835-845.
20. Park C, Zhang Y, Zhang X et al. PPARalpha agonist fenofibrate improves diabetic nephropathy in db/db mice. Kidney Int 2006; 69: 1511-1517.
21. Perico N, Codreanu I, Schieppati A et al. Pathophysiology of disease progression in proteinuric nephropathies. Kidney Int Suppl 2005; 67: S79-S82.
22. Kamijo Y, Hora K, Kono K et al. PPARalpha protects proximal tubular cells from acute fatty acid toxicity. J Am Soc Nephrol 2007; 18: 3089-3100. (Pubitemid 350223969)
23. Sugiyama M, Kinoshita K, Kishimoto K et al. Deletion of IL-18 receptor ameliorates renal injury in bovine serum albumin-induced glomerulonephritis. Clin Immunol 2008; 128: 103-108.
24. Ishigaki N, Yamamoto T, Shimizu Y et al. Involvement of glomerular SREBP-1c in diabetic nephropathy. Biochem Biophys Res Commun 2007; 364: 502-508. (Pubitemid 350026495)
25. Fan C, Pan J, Usuda N et al. Steatohepatitis, spontaneous peroxisome proliferation and liver tumors in mice lacking peroxisomal fatty acyl-CoA oxidase. Implications for peroxisome proliferator-activated receptor alpha natural ligand metabolism. J Biol Chem 1998; 273: 15639-15645. (Pubitemid 28298179)
26. Zhao Z, Lee YJ, Kim SK et al. Rosiglitazone and fenofibrate improve insulin sensitivity of pre-diabetic OLETF rats by reducing malonyl-CoA levels in the liver and skeletal muscle. Life Sci 2009; 84: 688-695.
27. Toyama T, Nakamura H, Harano Y et al. PPARalpha ligands activate antioxidant enzymes and suppress hepatic fibrosis in rats. Biochem Biophys Res Commun 2004; 324: 697-704. (Pubitemid 39345573)
28. Guerre-Millo M, Rouault C, Poulain P et al. PPAR-alpha-null mice are protected from high-fat diet-induced insulin resistance. Diabetes 2001; 50: 2809-2814. (Pubitemid 33733132)
29. Keech A, Simes R, Barter P et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005; 366: 1849-1861.
30. Guerre-Millo M, Gervois P, Raspé E et al. Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity. J Biol Chem 2000; 275: 16638-16642. (Pubitemid 30398891)
31. Jeong S, Han M, Lee H et al. Effects of fenofibrate on high-fat diet-induced body weight gain and adiposity in female C57BL/6J mice. Metabolism 2004; 53: 1284-1289. (Pubitemid 39222088)
32. Bahlmann FH, Song R, Boehm SM et al. Low-dose therapy with the longacting erythropoietin analogue darbepoetin alpha persistently activates endothelial Akt and attenuates progressive organ failure. Circulation 2004; 110: 1006-1012. (Pubitemid 39128626)
33. Bligh E, Dyer W. A rapid method of total lipid extraction and purification. Can J Biochem Physiol 1959; 37: 911-917.
34. Kume S, Haneda M, Kanasaki K et al. SIRT1 inhibits transforming growth factor beta-induced apoptosis in glomerular mesangial cells via Smad7 deacetylation. J Biol Chem 2007; 282: 151-158. (Pubitemid 47076643)
35. Takaya K, Koya D, Isono M et al. Involvement of ERK pathway in albumininduced MCP-1 expression in mouse proximal tubular cells. Am J Physiol Renal Physiol 2003; 284: F1037-F1045. (Pubitemid 36443589)